CVS's app is designed as a one-stop shop for customers to do everything from manage prescriptions to opening locked display ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

I am now over two months weeks into Mounjaro, the weekly injectable medication that contains Tirzepatide, an active ingredient that suppresses and regulates your appetite. Ozempic is perhaps the ...

The latest to join the ranks is the so-called “natural Mounjaro” drink for weight loss. Recipes vary slightly depending on which one you find, but the natural Mounjaro drink generally consists of ...

FTC Chair Lina Khan has the big three pharmacy benefit managers in sight—UnitedHealth's OptumRx, Cigna's Express Scripts and CVS Caremark Rx. © 2024 Fortune Media ...

The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for ...

Mounjaro (tirzepatide) is a brand-name drug prescribed to treat type 2 diabetes in adults. Mounjaro comes as a solution inside injection pens that you’ll administer weekly as a subcutaneous ...

The company attributed the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. “It’s always disappointing to miss your own ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

Pharmacy benefit managers CVS Caremark, OptumRx and Express Scripts inflated costs for specialty generic drugs to treat diseases such as cancer and HIV to the tune of $7.3 billion over six years ...